蛇黄肝炎汤含药血清对人肝癌细胞HepG-2增殖的抑制作用
|
摘要
目的探讨蛇黄肝炎汤含药血清对人肝癌细胞HepG-2增殖的影响。方法 25只大鼠随机分为1倍、2倍、4倍浓度含药血清组,复方环磷酰胺含药血清组(阳性药物血清组),空白血清组5个实验药物组,分别将不同浓度的蛇黄肝炎汤含药血清、阳性药物含药血清、空白血清与HepG-2细胞共同培养,采用四甲基偶氮唑蓝(MTT)比色法及细胞集落形成实验观察蛇黄肝炎汤含药血清体外对HepG-2细胞增殖、克隆形成能力的影响。结果与空白血清组相比较,2、4倍的蛇黄肝炎汤含药血清组吸光度值(OD值)均降低,差异均有统计学意义(P<0.05)。4倍含药血清随作用时间的延长,对HepG-2细胞的抑制率逐渐增加(P<0.05),当4倍浓度含药血清抑制时间为72 h时,抑制率达76.82%,与阳性药物血清组作用相当(抑制率达77.71%)。不同浓度的含药血清均能有效降低肿瘤细胞集落形成,与空白血清组相比差异均有统计学意义(P<0.05),且随着含药血清浓度增大细胞集落形成数逐渐降低,集落形成抑制率随含药血清浓度的增加呈逐渐升高的趋势。结论蛇黄肝炎汤含药血清具有抑制人肝癌细胞HepG-2体外增殖、降低其克隆形成能力作用。
Objective To explore the impacts of shehuang ganyan decoction- contained serum on human Hepg- 2 proliferation. Methods Twenty- five rats were randomized in the drug- contained serum groups of 1- time,2- time and 4- time concentrations,a compound cytoxan- contained serum group( the positive drug serum group and a blank serum group. HepG- 2 cells were cultivated with corresponding serum in each group. MTT colorimetry and cell colony formation experiment were used to observe the impacts of shehuang ganyan decoction- contained serum on in vitro HepG- 2 proliferation and clonality. Results Compared with the blank serum group,OD value was reduced in the shehuang ganyan decoction- contained serum groups of 2- time and 4- time concentrations,indicating the significant difference( P < 0. 05). With the effect duration of 4- time drug- contained serum,the inhibitive rate of HepG- 2 cells was increased gradually( P < 0. 05). In 72 h,the inhibitive rate was up to 76. 82%,similar to 77. 71% in the positive drug serum group. The drug- contained serum of different concentrations all reduced effectively the colony formation of cancer cell,presenting the significant differences as compared with the blank serum group( P < 0. 05). With the increase of the drug- contained concentration,the number of cell colony formation was reduced gradually and the inhibitive rate of colony formation was increased in tendency with the increase of drug- contained serum concentration. Conclusion The shehuang ganyan decoction- contained serum inhibits in vitro proliferation of HepG- 2 and reduces clonality.
Objective To explore the impacts of shehuang ganyan decoction- contained serum on human Hepg- 2 proliferation. Methods Twenty- five rats were randomized in the drug- contained serum groups of 1- time,2- time and 4- time concentrations,a compound cytoxan- contained serum group( the positive drug serum group and a blank serum group. HepG- 2 cells were cultivated with corresponding serum in each group. MTT colorimetry and cell colony formation experiment were used to observe the impacts of shehuang ganyan decoction- contained serum on in vitro HepG- 2 proliferation and clonality. Results Compared with the blank serum group,OD value was reduced in the shehuang ganyan decoction- contained serum groups of 2- time and 4- time concentrations,indicating the significant difference( P < 0. 05). With the effect duration of 4- time drug- contained serum,the inhibitive rate of HepG- 2 cells was increased gradually( P < 0. 05). In 72 h,the inhibitive rate was up to 76. 82%,similar to 77. 71% in the positive drug serum group. The drug- contained serum of different concentrations all reduced effectively the colony formation of cancer cell,presenting the significant differences as compared with the blank serum group( P < 0. 05). With the increase of the drug- contained concentration,the number of cell colony formation was reduced gradually and the inhibitive rate of colony formation was increased in tendency with the increase of drug- contained serum concentration. Conclusion The shehuang ganyan decoction- contained serum inhibits in vitro proliferation of HepG- 2 and reduces clonality.
引文
[1]孔祥廉,王云庭,黄安安,等.蛇黄肝炎合剂联合阿德福韦酯片治疗慢性乙型肝炎临床研究[J].新中医,2011,43(9):27-29.
[2]孔祥廉,王云庭,黄安安,等.蛇黄肝炎合剂联合阿德福韦酯片治疗e抗原阳性慢性乙型肝炎的疗效观察[J].亚太传统医药,2011,7(9):43-44.
[3]孔祥廉,林慧,梅全喜,等.蛇黄肝炎合剂对2215细胞分泌HBs Ag及HBe Ag的抑制作用[J].中华中医药学刊,2010,28(8):1703-1704.
[4]林慧,梅全喜,孔祥廉,等.蛇黄肝炎汤对小鼠急性肝损伤的保护作用研究[J].中国药房,2011,22(43):4038-4040.
[5]孔祥廉,梅全喜,林慧,等.蛇黄肝炎汤对小鼠碳粒廓清功能的影响[J].今日药学,2011,21(9):559-560.
[6]邱创衡.慢性乙型病毒性肝炎病毒复制与肝癌的相关性分析[J].中国医药指南,2013,11(17):185-186.
[7]夏欢,孙殿兴.HBV相关性肝癌的抗病毒研究现状[J].实用癌症杂志,2012,27(4):429-431.
[8]司徒镇强.细胞培养[M].西安:世界图书出版公司,2007:137-138.
[9]林慧,梅全喜.单味中药及其复方制剂抗肿瘤血清药理学研究进展[J].中国药房,2016,27(4):550-552.
[10]林慧,梅全喜,孔祥廉,等.白花蛇舌草治疗肝病的临床应用及机制研究概况[J].亚太传统医药,2011,7(10):173-175.
[11]林慧,梅全喜,孔祥廉,等.田基黄在肝病中的临床应用及药理作用研究概况[J].今日药学,2011,21(9):550-552.
[12]王灯节,刘廷,狄留庆,等.中药制剂指标性成分群辨识思路与方法解析[J].中草药,2015,46(23):3447-3454.
[2]孔祥廉,王云庭,黄安安,等.蛇黄肝炎合剂联合阿德福韦酯片治疗e抗原阳性慢性乙型肝炎的疗效观察[J].亚太传统医药,2011,7(9):43-44.
[3]孔祥廉,林慧,梅全喜,等.蛇黄肝炎合剂对2215细胞分泌HBs Ag及HBe Ag的抑制作用[J].中华中医药学刊,2010,28(8):1703-1704.
[4]林慧,梅全喜,孔祥廉,等.蛇黄肝炎汤对小鼠急性肝损伤的保护作用研究[J].中国药房,2011,22(43):4038-4040.
[5]孔祥廉,梅全喜,林慧,等.蛇黄肝炎汤对小鼠碳粒廓清功能的影响[J].今日药学,2011,21(9):559-560.
[6]邱创衡.慢性乙型病毒性肝炎病毒复制与肝癌的相关性分析[J].中国医药指南,2013,11(17):185-186.
[7]夏欢,孙殿兴.HBV相关性肝癌的抗病毒研究现状[J].实用癌症杂志,2012,27(4):429-431.
[8]司徒镇强.细胞培养[M].西安:世界图书出版公司,2007:137-138.
[9]林慧,梅全喜.单味中药及其复方制剂抗肿瘤血清药理学研究进展[J].中国药房,2016,27(4):550-552.
[10]林慧,梅全喜,孔祥廉,等.白花蛇舌草治疗肝病的临床应用及机制研究概况[J].亚太传统医药,2011,7(10):173-175.
[11]林慧,梅全喜,孔祥廉,等.田基黄在肝病中的临床应用及药理作用研究概况[J].今日药学,2011,21(9):550-552.
[12]王灯节,刘廷,狄留庆,等.中药制剂指标性成分群辨识思路与方法解析[J].中草药,2015,46(23):3447-3454.